Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z.
This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI. Now, they revisit the conversation to see what’s changed and what hasn’t.
Together, they chat through tech as a competitive differentiator for large companies, generative AI for drug development, and what Greg and BMS look for in potential partners. They also highlight the importance of being agile and adaptable while navigating the changing landscape of biotech, providing valuable insights for founders.
Jorge Conde is a general partner on the Bio + Health team at Andreessen Horowitz, focused on therapeutics, diagnostics, life sciences tools, and software.
Greg Meyers
Kris Tatiossian is the content lead, life sciences, on the Bio + Health team.
Olivia Webb is the editorial lead, healthcare, on the Bio + Health team.
Biology and the state of healthcare are undergoing radical shifts. Raising Health delves into dialogues with scientists, technologists, founders, builders, leaders, and visionaries as they explore how AI, engineering, and technology elevate health to new heights and create a system of enduring health for all.